In December 2025, the ReachTact TAVR Assistance System, independentlydeveloped by Zhicheng Medical Technology (Jiaxing) Co., Ltd., was officiallyacceptedby the special review and approval procedure for innovative medical devicesoftheNMPA. This milestone marks the system as the first TAVR robotic assistancesystemin China's structural heart disease field, representing a key stepforwardinthecommercialization and industrialization of domestic TAVR robotic assistancesystems.

In current interventional treatments for aortic stenosis (AS), TAVRhasbecomeincreasingly mature and widely adopted worldwide. However, a primarychallengeinTAVR procedures is the steep learning curve and the requirement for multi-personcoordination in operating the instruments, which places higher demandsonboththesurgical team and the operator's experience, thereby limiting broader adoptionofthetechnology.

In the future, this system could integrate with advanced technologiessuchas5Gtoenable remote surgeries, facilitating the expansion of high-quality medical resources,overcoming limitations of time, space, and resource availability, andensuringmorepatients have access to the most effective treatments.